A Single-Arm, Multicenter, Phase 1b Study With an Expansion Cohort to Evaluate Safety and Efficacy of Necitumumab in Combination With Abemaciclib in Treatment of Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 17 Oct 2017
At a glance
- Drugs Abemaciclib (Primary) ; Necitumumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Eli Lilly
- 22 Mar 2017 Status changed from recruiting to active, no longer recruiting.
- 07 Feb 2017 Planned End Date changed from 1 Oct 2018 to 12 Nov 2018.
- 07 Feb 2017 Planned primary completion date changed from 1 May 2017 to 26 Jun 2017.